Navigation Links
ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants

it is possible that ANA380/LB80380 used in combination with these existing drugs may help prevent the emergence of resistance. These new results are also consistent with previously reported clinical data showing that ANA380 is active in patients refractory to lamivudine."

"Clearly, we are encouraged by these study results and believe they support additional clinical evaluation to confirm the potential broad clinical utility of ANA380 in treating patients with chronic HBV infection," said In-Chull Kim, Ph.D., President and Chief Executive Officer of LG Life Sciences.

Anadys and LG Life Sciences entered into a Joint Development and License Agreement in April 2004 providing for the global development of ANA380 and pursuant to which Anadys acquired commercialization rights to ANA380 in North America, Europe, Japan and the rest of the world other than China, Korea, India and countries in Southeast Asia. Next steps for the program, including a proposed Phase IIb dose selection clinical trial, are under discussion between Anadys and LGLS.

Study Methods

HBV mutant strains were generated from a wild-type strain of HBV genotype D through site-directed mutagenesis. Mutant strains encoded polymerases resistant to lamivudine, adefovir, entecavir or telbivudine. Replicate HepG2 cell cultures were infected with HBV DNA using baculovirus vectors and were exposed to different concentrations of each drug for seven days. Viral DNA then was extracted and quantified. EC50 values, which were calculated from averages of three independent experiments, were used to evaluate susceptibility.

Clinical Background

ANA380 is an oral prodrug of ANA317 (LB80317), a nucleotide analog. Data from 62 HBV infected patients from a previous Phase II study showed that patients treated daily with ANA380 at 90 mg, 150 mg and 240 mg dose levels experienced reduction in plasma HBV viral DNA at 12 weeks of 3.9 log10, 3.9 log10 and 4.1 log10 units, respectively, (greate
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
7. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... company, today scheduled a conference call to discuss its ... 2013, ended April 30, 2013. The call will be ... The Company will report financial results for the second ... on Thursday, May 30, 2013. (Logo: ...
(Date:5/23/2013)... , May 23, 2013 More than ... may not benefit from chemotherapy and still have excellent ... launch of one of the largest sources of online ... website and interactive Facebook page provide recently diagnosed women ... can safely avoid chemotherapy. "We anticipate these ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3
... Nov. 4, 2010 Decision Resources, one of the ... healthcare issues, finds that biosimilar erosion of branded erythropoietin ... more rapid and more complete in the United States ... ESAs entered the European market in 2007. According to ...
... 4, 2010 NuView Life Sciences, Inc ("NuView"), ... proprietary target specific biomarkers for utilization with Positron ... its applications for the Qualifying Therapeutic Discovery Project ... The grants totaling just over $1.2 million dollars ...
Cached Medicine Technology:Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe 2NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010 2
(Date:5/24/2013)... Coral Springs, FL (PRWEB) May 24, 2013 ... to present May air dates for Charlotte, North Carolina. It ... home to many Fortune 500 companies. The city is populated ... top-notch healthcare organizations which cover residents in both North and ... program about all things medically-related can tune into WAXN-TV 64 ...
(Date:5/24/2013)... GA (PRWEB) May 24, 2013 CBT News.com ... Sales. Gonter joins the web-based retail automotive industry news organization ... , “I’m excited to join a group that’s so ... perfect example of how online video content is on the ... in the motorcycle business and segued into advertising at Cycle ...
(Date:5/24/2013)... Electric™ Energy Straws, an exciting new brand of ... and will be the lead sponsor on Munoz’s Chevy #26 ... Speedway. Munoz, who is part of Andretti Autosports’ fantastic five ... race, qualifying to be named the 2013 Indy 500 Fastest ... race. , While Munoz is grabbing headlines around the ...
(Date:5/24/2013)... American International College of Arts and ... agreement with Old Dominion University (ODU) that ... , The program will permit ODU students ... cell biology course, taught by AICASA’s faculty, for three ... of Antigua (AUA) College of Medicine , students will ...
(Date:5/24/2013)... Texas (PRWEB) May 24, 2013 ... range of products used outside the central laboratory, ... by a healthcare practitioner or by consumers. This ... coagulation, fertility and pregnancy, infectious and cardiovascular disease ... areas such as critical care, surgical and emergency ...
Breaking Medicine News(10 mins):Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 2Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 3Health News:AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3
... Practice Manager Notes Ease of Use, Time Savings, ... Healthcare, Inc. has,announced that West Michigan Orthopaedics, a ... is moving to the Intergy by Sage,practice management ... The three-physician group had been on The ...
... PARK, N.C., Dec. 11 Quintiles,Transnational Corp. today ... President and General Counsel., Previously Senior Vice ... Quintiles in 1998 as Vice President, European,Legal Affairs., ... and the clinical,research industry, having served the company ...
... Influenza Vaccination Into the New Year, BETHESDA, ... season,in full swing, getting vaccinated against influenza, commonly ... keep you and your family healthy. Too many,people ... in October and,November, but the National Foundation for ...
... Dec. 11 Amedica Corporation, an,orthopedic implants company ... the U.S. Food and Drug Administration,has granted a ... spinal implant., The Valeo VBR spinal implant ... surgical correction and stabilization of the thoracolumbar spine.,The ...
... Advance(R) and Similac(R) Isomil(R) Advance(R) Formulas Now ... Available in Nipple-Ready 8-Fluid-Ounce Bottles, COLUMBUS, Ohio, Dec. ... moms commissioned by Abbott,s Similac brand, packing the,diaper bag ... 30 minutes.,Nearly all moms surveyed (98 percent) agree that ...
... cells (progenitor cells) to treat the damage to cardiac ... Emory University School of Medicine. , The study investigators--Emory ... update their colleagues on its progress at the American ... "This is one of the first trials where patients ...
Cached Medicine News:Health News:West Michigan Orthopaedics Migrates to Intergy by Sage Practice Management System 2Health News:West Michigan Orthopaedics Migrates to Intergy by Sage Practice Management System 3Health News:Don't Let Influenza Ruin Your Holidays - Get Vaccinated 2Health News:Don't Let Influenza Ruin Your Holidays - Get Vaccinated 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:Similac(R) Survey Finds New Moms Want Convenient, Time-Saving Baby Products 2Health News:Similac(R) Survey Finds New Moms Want Convenient, Time-Saving Baby Products 3Health News:Adult stem cell heart attack study updated at American Society for Hematology Meeting 2
... H-1200 Fast Flow Fluid Warmer, a new generation ... the existing Level 1 Fast Flow Fluid Warmer ... Fluid Warmer incorporates the features of integrated air ... deliver warm fluids as fast as 1,000 ml/minute ...
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
... Flexible excellence for patients and clinicians., ... the Aestiva/5 anesthesia system, the Aestiva/5 MRI ... anesthesia systems with a fully functional, integrated ... (300 Gauss, 1.5 T active shielded magnet), ...
... meeting today's and tomorrow's needs in anesthesia procedures., ... solutions in its field today. This compact system ... revolving arm holds the complete user interface. A ... that there is less need to move the ...
Medicine Products: